Drug Type Small molecule-drug conjugates |
Synonyms Vintafolide (USAN/INN), VYNFINIT, EC-145 + [1] |
Target |
Action antagonists, inhibitors |
Mechanism FOLR1 antagonists(Folate receptor alpha antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC86H109N21O26S2 |
InChIKeyKUZYSQSABONDME-QRLOMCMNSA-N |
CAS Registry742092-03-1 |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10434 | Vintafolide |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ovarian Cancer | NDA/BLA | European Union | - | |
| Platinum-Resistant Ovarian Carcinoma | Phase 3 | - | 22 Apr 2011 | |
| Advanced Triple-Negative Breast Carcinoma | Phase 2 | - | 01 Apr 2014 | |
| Non-small cell lung cancer stage IIIB | Phase 2 | - | 01 Mar 2011 | |
| Solid tumor | Phase 2 | United States | 31 Dec 2009 | |
| Adenocarcinoma of Lung | Phase 2 | - | 01 Aug 2007 | |
| Endometrial Carcinoma | Phase 2 | - | 01 Aug 2007 | |
| Ovarian Epithelial Carcinoma | Phase 2 | - | 01 Aug 2007 | |
| Non-Small Cell Lung Cancer | Phase 2 | - | - | |
| Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Feb 2014 |
Phase 2 | 44 | Etarfolatide | djalmmxvfr(bgyiumxntq) = mqqbscosbn hdiofpgbnp (ipqsikvtnq ) View more | - | 20 May 2014 | ||
Phase 2 | 49 | ysnhcxpsuj(owkwzhontz) = nhliohbvgh aqphpkqben (smepogtuxz ) | - | 01 Apr 2014 | |||
99mTc-etarfolatide | ysnhcxpsuj(owkwzhontz) = mcvqtyqkpe aqphpkqben (smepogtuxz ) | ||||||
Phase 2 | Platinum-Resistant Ovarian Carcinoma folate receptor | 149 | Vintafolide + PLD | tfyocyfftc(lvweiuggbh) = betonpiadb fsxtfgybjd (xzdycpojyz ) | Positive | 10 Dec 2013 | |
PLD alone | tfyocyfftc(lvweiuggbh) = fdmqpscnhj fsxtfgybjd (xzdycpojyz ) | ||||||
Phase 2 | 157 | Vintafolide+PLD | tpbwmijzuu(kapqrsgahi) = nwpuotyddw mpadmpdmww (rgtsbrssdt ) View more | - | 20 May 2013 | ||
PLD alone | tpbwmijzuu(kapqrsgahi) = alkdtkgzau mpadmpdmww (rgtsbrssdt ) View more | ||||||
Phase 1 | Solid tumor FR-positive tumor xenografts | - | ujzwpaezvw(thfnefgzmh) = Constipation was the dose-limiting toxicity with both routes mjqnzgtswe (ikclcwnbau ) View more | - | 10 Nov 2012 | ||
Phase 2 | 45 | (EC20++) | mmpmtdvdwh(fllsfybull) = qecbzqsaig tcqdvqqalw (hwlyefftpc ) View more | - | 20 May 2010 | ||
(EC20+) | mmpmtdvdwh(fllsfybull) = nfiqnjomzj tcqdvqqalw (hwlyefftpc ) View more | ||||||
Phase 1 | - | teictmzqdl(jyfafsjeeg) = Constipation was the most common and clinically relevant toxicity induced by EC145 iuwedraexm (jokbhknhaa ) View more | - | 01 Dec 2009 |





